Low Abundance Biomarkers of Inflammation Quantified in Crohn's Disease

The assays showed that anti-TNF-α drugs reduced plasma free cytokine concentrations.

Quanterix Corporation (Cambridge, MA, USA), a company enabling a new generation of molecular diagnostic tests based on its Single Molecule Array (SiMoA) technology, announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease. The study was published online on July 27, 2011, in the Journal of Immunological Methods.

Martin Madaus, PhD, Quanterix executive chairman commented, "Although larger studies will be needed to fully understand the potential utility of cytokine measurements in the diagnosis of inflammatory diseases such as Crohn's, these results provide some indication of how sensitive and precise protein measurements enabled by SiMoA could be used clinically."

SiMoA technology is being developed by Quanterix Corporation for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields a 1,000–fold improvement in sensitivity compared with conventional immunoassays. SiMoA will enable life science investigators to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection, and disease monitoring.

Related Links:
Quanterix Corporation